Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan
NCT05681273Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of chiglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Akeso, Inc. Primary endpoints: Maximum Plasma Concentration up to 72 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 72 hours and 1 more. Started Feb 2023; status: completed.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05681273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681273.